RxDoctor Payments Data

Alan Lyne, MD

Family Medicine · Santa Paula, CANPI 1083707087

Payments from drug & device makers

$2,609in general payments, 2019–2025

Across 59 payments — averaging $44.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$476
  • Abbott$246
  • Lilly USA, LLC$217
  • Sanofi-aventis U.S. LLC$150
  • Amgen$96
  • plus $252 from 9 others

What the payments were for

  • Speaking & faculty fees$1506%
  • Food & beverage$2,44894%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,609 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$26,064
Medicare patients
56
Services billed
4,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin65$66,858
OzempicSemaglutide22$31,295
XareltoRivaroxaban23$30,002
RybelsusSemaglutide15$27,751
JanuviaSitagliptin Phosphate22$20,635
FarxigaDapagliflozin Propanediol17$12,701
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,156
Atorvastatin Calcium414$3,632
PremproEstrogen,con/M-Progest Acet13$3,075
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen88$2,160
Metformin Hcl ErMetformin Hcl152$1,986
Metoprolol Succinate113$1,765
Levothyroxine Sodium112$1,625
Omeprazole89$1,349
Losartan Potassium115$1,302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$21$66,85865 claims
Novo NordiskOzempic, Rybelsus$476$59,04737 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,171$20,85730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Santa Paula

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →